Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

End Of Exanta: AstraZeneca Drops Drug After New Report Of Liver Injury

This article was originally published in The Pink Sheet Daily

Executive Summary

The firm is pulling its U.S. application for the anticoagulant and will remove the drug from European markets following a report of serious liver injury.

You may also be interested in...



AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.

AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.

Boehringer Ingelheim’s Dabigatran Demonstrates Non-Inferiority To Lovenox

The drug maker is in discussions with U.S. regulators regarding submission for venous thromboembolism, but has not released a filing timeline.

Related Content

Topics

UsernamePublicRestriction

Register

ID1131516

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel